Skin toxicities are the most common adverse effects of epidermal growth factor receptor inhibitors(EGFRI).It can result in significant physical and psyehological discomfort,and even leads to interruption or dose modification,and consequently affect the curative effect. Nowadays this adverse effect has attracted lot of attention.It is proposed that clinical management and treatment measures for skin toxicities should be further studied to improve the patients life quality,and guarantee the continuity and best curative effect of the treatment.But more researches on the pathogenesis and its prognostic significance are still expected.

Objective: To investigate the the sleep quality of frontier armymen located in the Gobi desert and its corre- lated factors. Methods: The sleep quality of 302 frontier armymen located in the Gobi desert was assessed with Pittsburgh Sleep Quality Index (PQSI). Results: The total scores of PQSI was 6.79?3.39,and 49.7% of the armymen suffered from sleep problems.The total scores of PQSI were correlated with health status,satisfaction with work,influence by the relation- ship with opposite sex,pressure from study and work,et al. Conclusion: The sleep quality problem of the frontier armymen located in the Gobi desert was more than normal people, and special measures should be taken to improve their sleep quality.

In recent years,major advances have been made in our understanding of the pathogenesis,epidemiology,pathophysiology and in the treatment of pulmonary hypertension.Accordingly,the definition,clinical classification and treatment guidelines of pulmonary hypertension have been updated constantly.This article will focus on the new definition,classification and treatment of pulmonary hypertension.

High mobility group box 1 protein (HMGB1), a damage-associated molecular pattern, exists ubiquitously in the cells of mammals. It contributes to maintaining the structure of nucleosome and modulating transcription of gene in nuclei. Extracellular HMGB1 plays two-way roles in promoting inflammatory and tissue repair. Released actively as well as passively following cytokine stimulation during cell death, HMGB1 may act as a late inflammatory factor and an endogenous damage-associated molecular pattern recognized by its receptors. And it may mediate the occurrence, development and outcome of the inflammatory injury of digestive system diseases, such as gastric mucosal injury, inflammatory bowel-disease, liver injury, pancreatitis, and so on. This review mainly concerns the research progresses of HMGB1 in the inflammatory injury of digestive system diseases. At the same time, HMGB1 itself, or as a therapeutic target, can promote tissue repair.
Animals ; Digestive System Diseases ; pathology ; HMGB1 Protein ; metabolism ; Humans ; Inflammation ; pathology

Liquichip is a new type of biochip emerging in the 1990s, which is integrated flow cytometry, laser technology, digital signal processing and traditional chemical technology with the greatest features of high-throughput and high-flexibility. Luminex has promoted new products from Luminex 100/200 to Flexmap 3D. This is an introduction to the development, principle, and application of Luminex liquichip.

Objective To study the knowledge,attitude and behavior of six-step hand-washing procedure in the infectious department.Methods Questionnaires were used to investigate the knowledge,acceptability and compliance of six-step hand-washing procedure in the clinical workers in four class a tertiary hospitals of Guangdong province.Results 168 medical staff all knew the six-step hand-washing procedure(100%).However,the rates of acceptability and compliance varied from one occasion to another.The knowledge about hand-washing scored(4.36±2.08),(26.08±6.14)for attitude,The correlation coefficient was 0.358.Conclusions Though the importance of hand-washing has been confirmed and accepted by the medical staff,their compliance of hand-washing during work is not very optimistic.

Objective To study the significance of acute pancreatitis AP complications by acid-base distur-bance. Methods The arterial blood gas, serum electrolytes parameter and clinical data of 85 patients were analyzed.Results Acid-base disturbance of different types commonly existed in the early stage of AP patients. There are sig-nificant statistical differences in the indices of PaO2, PaCO2, SaO2 between group MAP and group SAP( P < 0.05 or P < 0.01 ). Conclusion Acid-base disturbance are very common in the AP patients and this-will make the condition worse,they should be treated promptly.

Objective To investigate the potential complications of renal transplant patients, to develop appropriate treatment programs to reduce the incidence. Methods Clinical data of 42 patients with renal transplantation were retrospectively analyzed. Blood type of the donors and recipients were same in 32 cases; Blood type of the donors was 0 and recipients blood type was A,3 cases;Donors blood type was 0 and recipients blood type was B,2 cases; Donors blood type was O and recipients blood type was AB,4 cases; Donors blood type was B and recipients blood type was AB,lease. Results In alll cases, there were acute rejection in 2 cases,pulmonary infection in 2 cases, wound infection in 1 case,urinary leakage in 1 case,urinary tract infection in 2 cases.42 cases were all cured up. One patient lost kidney function and required dialysis therapy 4 years after kidney transplantation, the remaining 40 patients were good. Conclusion Early detection and timely management of complications of renal transplantation played a very important role in improving the survival rate.

Objective To compare the efficacy of 10-day sequential therapy (including rabeprazole amoxillin clarithromycin tinidazole) and 7-day traditional trigeminy therapy (including rabeprazole amoxillin and clarithromycin) in patients with duodenobulbar ulcer and Hp infection. Methods Ninty-five patients with duodenobulbar ulcer and Hp infection were enrolled into the study and divided into two groups randomly:sequential therapy group and traditional trigeminy therapy group. Patients in the first group received 10-day sequential medications:rabeprazole 10 mg plus amoxillin 1 g for the first 5 days,followed by rabeprazole 10 mg plus clarithromycin 500 mg and tinidazole 500 mg for another 5 days;while in the second group patients received the standard 7-day traditional triple medications:rabeprazole 10 mg plus clarithromycin 500 mg and tinidazole 400 mg. All drugs were given twice daily. All patients received rabeprazole 10 mg daily following the two types of therapys for another four weeks. Hp statuses were assessed by rapid urease test and 14C urea breath test at baseline and 4 weeks after completion of the treatment. Ulcer cicatrization was assessed by gastroscope. Results The eradication rate of Hp infection was significantly higher in sequential group than triple group (89.5%vs. 70. 2%, P ＜ 0. 05 ), but we found no statistically significant difference in the comparison of the ulcer cicatrization rate between sequential group and triple group ( 87.5% vs. 82. 9%, P ＞ 0. 05 ). Conclusion Sequential therapy had a better Hp eradication effect than standard triple therapy, but the eradication rate was very close between the two therapys.

Objective:To perform a meta-analysis of randomized controlled trials ( RCTs) in multiple sclerosis ( MS) patients to evaluate the efficacy and safety of alemtuzumab.Methods: We searched PubMed,EMBASE,the Cochrane Library and so on up to February 2015 using the keywords:′multiple sclerosis′or ′MS′and the drug names:alemtuzumab.Two authors independently selected the articles and extracted the data.We performed meta-analysis using Review Manager ( RevMan) version 5.3 software.Results:Three RCTs with a total of 1 695 patients were selected.Compared to the interferon beta,the number of gadolinium-enhancing lesions ( odds ratio (OR)=0.33,95% Confidence interval (CI)=[0.23,0.48],P<0.000 01),the cumulative probability of sustained disability (Or=0.51,95%CI=[0.38,0.69],P<0.000 1) and the proportion of patients who had at least one relapse of MS(Or=0.42,95%CI=[0.34,0.52],P<0.000 1) were significantly less in the alemtuzumab group,meanwhile the number of new T2-hyperintense lesions (Or=0.10,95%CI=[0.01,1.75],P=0.11) showed no significant difference.Comparing adverse events between two groups, alemtuzumab treatment did not increase the frequency of serious adverse events (Or=1.00,95% CI=[0.80,1.26],P=0.99) but increase the frequency of any adverse events (Or=2.29,95% CI=[1.40,3.75],P=0.001).Conclusion: Alemtuzumab is a relatively effective and safe treatment for MS.